# TABLE OF CONTENTS

## HIGHLIGHTS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>941</td>
<td>Selected Articles from This Issue</td>
<td></td>
</tr>
</tbody>
</table>

## CANCER GENES AND NETWORKS

### 943 Fibrinogen Alpha Chain Knockout Promotes Tumor Growth and Metastasis through Integrin–AKT Signaling Pathway in Lung Cancer

Meng Wang, Guangxin Zhang, Yue Zhang, Xuelian Cui, Shuaibin Wang, Song Gao, Yicun Wang, Ying Liu, Jieyoo H. Bae, Wei-Hsiung Yang, Lei S. Qi, Lihong Wang, and Runhua Liu

### 955 NF-κB-Activated miR-574 Promotes Multiple Malignant and Metastatic Phenotypes by Targeting BNIP3 in Thyroid Carcinoma

Zhe-Jia Zhang, Qian Xiao, and Xin-Ying Li

### 968 Targeting Mutant PPP1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib

Zhaohui Wang, Cheng Xu, Bill H. Diplas, Casey J. Moure, Chiu-Pu Jason Chen, Lee H. Chen, Changsheng Du, Huishan Zhu, Paula K. Greer, Liwei Zhang, Yiping He, Matthew S. Waitkus, and Hai Yan

### 981 Growth-Inhibitory Activity of Bone Morphogenetic Protein 4 in Human Glioblastoma Cell Lines Is Heterogeneous and Dependent on Reduced SOX2 Expression

A C Erika Dalmo, Patrik Johansson, Mia Niklasson, Ida Gustavsson, Sven Nelander, and Bengt Westermark

### 992 Aquaporin-9, Mediated by IGF2, Suppresses Liver Cancer Stem Cell Properties via Augmenting ROS/β-Catenin/FOXO3a Signaling

Xi Zheng, Chuanfei Li, Keji Yu, Shasha Shi, Hongyu Chen, Yanzhi Qian, and Zhechuan Mei

### 1004 Targeting NAD⁺ Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance


### 1018 The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers


### 1028 Targeting Opsin4/Melanopsin with a Novel Small Molecule Suppresses PKC/RAF/MEK/ERK Signaling and Inhibits Lung Adenocarcinoma Progression

Quishi Wang, Tianshun Zhang, Xiaoyu Chang, Keke Wang, Mei-Hyun Lee, Wei-Ya Ma, Kangdong Liu, and Zigang Dong

### 1039 Iron Regulatory Protein 2 Exerts its Oncogenic Activities by Suppressing TAp63 Expression

Yanhong Zhang, Xiuli Feng, Jin Zhang, and Xinxin Chen

### 1050 Mesenchymal and MAPK Expression Signatures Associate with Telomerase Promoter Mutations in Multiple Cancers

Josh Lewis Stern, Grace Hihshman, Kevin Hu, Sarah E. Ferrara, James C. Costello, William Kim, Pablo Tamayo, Thomas R. Cech, and Franklin W. Huang

### 1063 Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a

Tengteng Yu, Chenxing Du, Xiaoke Ma, Weiwei Sui, Zhen Yu, Lanting Liu, Lei Zhao, Zhongqing Li, Jie Xu, Xiaojing Wei, Wen Zhou, Shuhui Deng, Dehui Zou, Gang An, Yu-Tzu Tai, Guido Tricot, Kenneth C. Anderson, Lugui Qiu, Fenghuang Zhan, and Mu Hao

## CELL FATE DECISIONS

### 1074 Drug Targeting the Actin Cytoskeleton Potentiates the Cytotoxicity of Low Dose Vincristine by Abrogating Actin-Mediated Repair of Spindle Defects

Yao Wang, Jeffrey H. Stear, Ashleigh Swain, Xing Xu, Nicole S. Bryce, Michael Carnell, Irina B. Alieva, Vera B. Dugina, Timothy P. Cripe, Justine Stehn, Edna C. Hardeman, and Peter W. Gunning
**TABLE OF CONTENTS**

**METABOLISM**

1088  
**Targeting Fatty Acid Oxidation to Promote Anoikis and Inhibit Ovarian Cancer Progression**  
Brandon T. Sawyer, Lubna Qamar,  
Tomomi M. Yamamoto, Alexandra McMellen,  
Zachary L. Watson, Jennifer K. Richer, Kian Behbakht,  
Isabel R. Schlaepfer, and Benjamin G. Bitler

**TUMOR MICROENVIRONMENT AND IMMUNOBIOLOGY**

1099  
**Urothelial Carcinoma of the Bladder Induces Endothelial Cell Activation and Hypercoagulation**  
Axel John, José R. Robador, Sabine Vidal-y-Sy,  
Pia Houdek, Ewa Wladykowski, Cagatay Günes,  
Christian Bolenz, Stefan W. Schneider,  
Alexander T. Bauer, and Christian Gorzelanny

**CORRECTION**

1110  
**Correction: Circular RNA hsa_circ_0014130 Inhibits Apoptosis in Non–Small Cell Lung Cancer by Sponging miR-136-5p and Upregulating BCL2**

**ABOUT THE COVER**

Proliferative immortality and subversion of the Hayflick limit represents a key hallmark of cancer. In many tumors, this is achieved by elevated expression of telomerase reverse transcriptase (TERT), the catalytic subunit of the telomerase holoenzyme which stabilizes telomeres. TERT promoter mutations have been identified as one possible mechanism by which this can be achieved. The cover depicts an Onco-GPS Map of the Cancer Cell Line Encyclopedia, with dots representing the individual cancer samples color-coded according to the enrichment of an epithelial-mesenchymal transition (EMT) transcriptional signature (blue dots indicate a more epithelial signature, while red indicates EMT). The authors found that TERT promoter mutations were tied to gene expression programs that drive cells toward EMT-associated gene expression programs, potentially explaining why this class of mutations is associated with more aggressive cancers and worse outcomes. For more information, see the article on page 1050.